Stephanie Kim joined Acadia in 2023 as Senior Vice President, Regulatory Affairs, where she is responsible for leading the regulatory affairs function.
Ms. Kim brings extensive leadership experience in regulatory affairs with the development and implementation of global regulatory strategies for new products and life-cycle management of marketed products. Her expertise spans early development through approval and post-marketing in multiple areas including rare diseases, CNS, oncology, and advanced therapy medicines.
Ms. Kim joined Acadia from Ultragenyx Pharmaceuticals, where she was Vice President of Regulatory Affairs and led a team that oversaw global regulatory strategies for the development, registration, and lifecycle management of Ultragenyx assets in rare bones, neurology, and metabolic disease areas. Over the course of her career of nearly three decades, Stephanie has directed regulatory affairs at various pharmaceutical companies, including AstraZeneca, Amgen, and BioMarin.
She holds a bachelor’s degree in Biochemistry and a Master of Business Administration from the University of California, Davis.